

**Vascular Disrupting Agents Market, 2021-2030:
Distribution by Target Indications (Chemotherapy-
Induced Neutropenia, Glioblastoma, Hepatocellular
Carcinoma, Malignant Pleural Mesothelioma, Non-
Small Cell Lung Cancer, Prostate Cancer, Recurrent
Platinum Resistant Ovarian Cancer, Transitional Cell
Cancer of Renal Pelvis and Ureter), Therapeutic Area
(Hematological Malignancies, Solid Tumors and Other
Therapeutic Areas), Type of Molecule (Small Molecule
(Tubulin Binding Agents and Flavonoids) and Ligand-
Directed Agents) and Ligand-Directed Agents), Type
of Therapy (Monotherapy, Combination Therapy And
Both), Route of Administration (Oral, Intravenous),
and Key Geographical Regions (North America,
Europe, Asia-Pacific, Latin America, Middle East and
North Africa, and Rest of the World)**

<https://marketpublishers.com/r/V6A64868934FEN.html>

Date: April 2021

Pages: 295

Price: US\$ 4,799.00 (Single User License)

ID: V6A64868934FEN

Abstracts

The vascular disrupting agents market is expected to reach USD 23 million in 2021 and anticipated to grow at a CAGR of 65% during the forecast period 2021-2030.

Solid tumors constitute roughly 90% of diagnosed cancer cases, driving extensive efforts towards developing innovative anticancer therapies tailored for these types of

cancers. Over the past five years, the United States Food and Drug Administration (USFDA) has approved over 100 drugs for diverse cancer treatments. Despite these advancements, the increasing global exposure to various carcinogens and risk factors necessitates the development of more targeted and potent drugs or therapies to effectively combat this complex and life-threatening disease. The rapid growth of malignant cell masses that characterize solid tumors emphasizes the critical role of angiogenesis and adequate blood supply in sustaining the tumor population. Consequently, targeting tumor vasculature remains a compelling and promising approach in therapeutic pursuits. Vascular disrupting agents (VDAs) are interventions aimed at established tumor vasculature, thereby disrupting blood flow to cancerous tissues.

Currently, several small molecule VDAs are either under development or have been developed to address various oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma, and ovarian cancer. Additionally, combination therapies that integrate VDAs with conventional chemotherapy, radiation therapy, and radioimmunotherapy have shown significant clinical responses in various animal models.

Significantly, the advancements in this field receive substantial support from the National Institutes of Health, with research grants totaling USD 95 million disbursed since 2016. Driven by promising clinical research outcomes, this specialized yet burgeoning domain is poised for robust market growth in the foreseeable future. Early entrants are expected to gain a competitive edge as pioneers in this evolving landscape.

Report Coverage

Examine the vascular disrupting agents market by categorizing it based on indications, therapeutic areas, molecules, therapy types, administration routes, and geographical regions.

Analyze market growth factors like drivers, restraints, opportunities, and challenges.

Evaluate potential market advantages and obstacles, focusing on the competitive landscape for leading players.

Forecast revenue for market segments across six major regions.

Assess the current landscape of vascular disrupting agents, detailing developmental stages of product candidates, therapeutic areas, molecule types, therapy types, and administration routes. Provide a comprehensive list of companies involved in this development, considering establishment year, company size, and headquarters location.

Present detailed profiles of prominent market players based on their pipeline volume, including company overview, financial information, lead drug candidates' descriptions, development status, indications, mode of action, therapy type, recent developments, and future forecasts.

Conduct an in-depth analysis of completed, ongoing, and planned clinical studies on vascular disrupting agents. Highlight trends in trial status, patient population, regional distribution, molecule types, developmental phases, study designs, leading industry and non-industry players, focus, and key indications.

Review over 750 peer-reviewed scientific articles on vascular disrupting agents published between 2016 and January 2021. Analyze trends in publication years, emerging focus areas, keywords, indications, therapeutic areas, research journals, and notable authors.

Analyze grants awarded to research institutes between 2016 and January 2021 related to vascular disrupting agents. Parameters include the year of award, amount, administering institute, support period, grant type, purpose, activity code, focus areas, popular departments, recipient organization types, highlighting popular recipients, program officers, and regional distribution.

Compile a list of key opinion leaders (KOLs) in the vascular disrupting agents market. Assess their prominence and activity using a 2x2 matrix representation. Create a world map indicating the locations of eminent scientists/researchers. Evaluate KOL expertise based on publications, citations, clinical trial participation, affiliations, and professional networks available on ResearchGate.

Key Market Companies

AGC Biologics

Avid Bioservices

Bionomics

Mateon Therapeutics

Myrexis

VBL Therapeutics

Contents

1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Overview of Vascular Disrupting Agents
 - 3.2.1. Mechanism of Action of Vascular Disrupting Agents
- 3.3 Types of Vascular Disrupting Agents
 - 3.3.1. Small Molecule Vascular Disrupting Agents
 - 3.3.1.1. Tubulin Binding Agents
 - 3.3.1.2. Flavonoids
 - 3.3.2. Ligand Directed Vascular Disrupting Agents
- 3.4. Benefits of Vascular Disrupting Agents
- 3.5. Challenges Associated with Vascular Disrupting Agents
- 3.6. Future Perspectives

4. VASCULAR DISRUPTING AGENTS MARKET LANDSCAPE

- 4.1. Chapter Overview
- 4.2. Vascular Disrupting Agents: Development Pipeline
 - 4.2.1. Analysis by Phase of Development
 - 4.2.2. Analysis by Therapeutic Area
 - 4.2.3. Analysis by Target Disease Indication
 - 4.2.4. Analysis by Phase of Development and Target Disease Indication
 - 4.2.5. Analysis by Type of Molecule
 - 4.2.6. Analysis by Target Disease Indication and Type of Molecule
 - 4.2.7. Analysis by Type of Therapy
 - 4.2.8. Analysis by Route of Administration
 - 4.2.9. Analysis by Potential Combination Therapeutics
- 4.3. Vascular Disrupting Agents: Developer Landscape

- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters
- 4.3.4. Leading Players: Analysis by Number of Drug Candidates

5. COMPANY PROFILES

- 5.1. Chapter Overview
- 5.2. AGC Biologics
 - 5.2.1. Company Overview
 - 5.2.2. Drug Portfolio: Vascular Disrupting Agents
 - 5.2.2.1. Drug Profile: NGR-TNF
 - 5.2.3. Recent Developments and Future Outlook
- 5.3. Avid Bioservices
 - 5.3.1. Company Overview
 - 5.3.2. Financial Information
 - 5.3.3. Drug Portfolio: Vascular Disrupting Agents
 - 5.3.3.1. Drug Profile: Bavituximab
 - 5.3.4. Recent Developments and Future Outlook
- 5.4. Bionomics
 - 5.4.1. Company Overview
 - 5.4.2. Financial Information
 - 5.4.3. Drug Portfolio: Vascular Disrupting Agents
 - 5.4.3.1. Drug Profile: BNC105
 - 5.4.4. Recent Developments and Future Outlook
- 5.5. Mateon Therapeutics
 - 5.5.1. Company Overview
 - 5.5.2. Drug Portfolio: Vascular Disrupting Agents
 - 5.5.2.1. Drug Profile: CA4P
 - 5.5.2.2. Drug Profile: OXi4503
 - 5.5.3. Recent Developments and Future Outlook
- 5.6. Myrexix
 - 5.6.1. Company Overview
 - 5.6.2. Drug Portfolio: Vascular Disrupting Agents
 - 5.6.2.1. Drug Profile: MPC-6827
 - 5.6.3. Recent Developments and Future Outlook
- 5.7. VBL Therapeutics
 - 5.7.1. Company Overview
 - 5.7.2. Financial Information

5.7.3. Drug Portfolio: Vascular Disrupting Agents

5.7.3.1. Drug Profile: VB-111

5.7.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

6.1. Chapter Overview

6.2. Scope and Methodology

6.3. Vascular Disrupting Agents: Clinical Trial Analysis

6.3.1. Analysis by Trial Registration Year

6.3.2. Analysis by Trial Registration Year and Trial Status

6.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled

6.3.4. Analysis by Trial Phase

6.3.5. Analysis by Trial Phase and Number of Patients Enrolled

6.3.6. Geographical Analysis by Number of Clinical Trials

6.3.7. Geographical Analysis by Number of Patients Enrolled

6.3.8. Analysis by Study Design

6.3.9. Analysis by Trial Focus

6.3.10. Analysis by Drug Molecule

6.3.11. Analysis by Key Indications

6.3.12. Analysis by Type of Sponsor / Collaborator

6.3.13. Most Active Industry Players: Analysis by Number of Registered Trials

6.3.14. Most Active Non-Industry Players: Analysis by Number of Registered Trials

7. PUBLICATION ANALYSIS

7.1. Chapter Overview

7.2. Scope and Methodology

7.3. Vascular Disrupting Agents: List of Recent Publications

7.3.1. Analysis by Year of Publication

7.3.2. Emerging Focus Areas

7.3.3. Analysis by Popular Keywords

7.3.4. Analysis by Target Disease Indications

7.3.5. Analysis by Therapeutic Area

7.3.6. Popular Journals: Analysis by Number of Publications

7.3.7. Popular Journals: Analysis of Journal Impact Factor

7.3.8. Most Popular Authors: Analysis by Number of Publications

8. ACADEMIC GRANTS ANALYSIS

- 8.1. Chapter Overview
- 8.2. Scope and Methodology
- 8.3. Vascular Disrupting agents: Academic Grants Analysis
 - 8.3.1. Analysis by Year of Grant Award
 - 8.3.2. Analysis by Amount Awarded
 - 8.3.3. Analysis by Administering Institute Center
 - 8.3.4. Analysis by Support Period
 - 8.3.5. Analysis by Administering Institute Center and Support Period
 - 8.3.6. Analysis by Type of Grant Application
 - 8.3.7. Analysis by Activity Code
 - 8.3.8. Word Cloud Analysis: Emerging Focus Areas
 - 8.3.9. Popular Recipient Organizations: Analysis by Number of Grants
 - 8.3.10. Prominent Program Officers: Analysis by Number of Grants
 - 8.3.11. Regional Distribution of Recipient Organizations

9. KOL ANALYSIS

- 9.1. Chapter Overview
- 9.2. Assumptions and Methodology
- 9.3. Principal Investigators of Vascular Disrupting Agents Focused Clinical Trials
 - 9.3.1. Geographical Distribution of KOLs
 - 9.3.2. Analysis by Type of Organization (KOL Affiliation)
 - 9.3.3. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
- 9.4. Prominent Key Opinion Leaders (KOLs)
- 9.5. KOL Benchmarking: Roots Analysis versus Third-Party Scoring (ResearchGate Score)
- 9.6. Profiles of Most Active KOLs
 - 9.6.1. KOL Profile: KOL A
 - 9.6.2. KOL Profile: KOL B
 - 9.6.3. KOL Profile: KOL C
 - 9.6.4. KOL Profile: KOL D
 - 9.6.5. KOL Profile: KOL E
 - 9.6.6. KOL Profile: KOL F

10. MARKET SIZING AND OPPORTUNITY ANALYSIS

- 10.1. Chapter Overview
- 10.2. Scope and Limitations

10.3. Key Assumptions and Forecast Methodology

10.4. Overall Vascular Disrupting Agents Market, 2021-2030

10.4.1. Vascular Disrupting Agents Market: Distribution by Target Indication

10.4.2. Vascular Disrupting Agents Market: Distribution by Therapeutic Area

10.4.3. Vascular Disrupting Agents Market: Distribution by Type of Molecule

10.4.4. Vascular Disrupting Agents Market: Distribution by Type of Therapy

10.4.5. Vascular Disrupting Agents Market: Distribution by Route of Administration

10.4.6. Vascular Disrupting Agents Market: Distribution by Geography

10.4.7. Product-wise Sales Forecast

10.4.7.1. Bavituximab (Avid Bioservices)

10.4.7.1.1. Target Patient Population

10.4.7.1.2. Sales Forecast (USD Million)

10.4.7.1.3. Net Present Value (USD Million)

10.4.7.1.4. Value Creation Analysis

10.4.7.2. Icaritin (Beijing Shenogen Biomedical)

10.4.7.2.1. Target Patient Population

10.4.7.2.2. Sales Forecast (USD Million)

10.4.7.2.3. Net Present Value (USD Million)

10.4.7.2.4. Value Creation Analysis

10.4.7.3. NGR-TNF (AGC Biologics)

10.4.7.3.1. Target Patient Population

10.4.7.3.2. Sales Forecast (USD Million)

10.4.7.3.3. Net Present Value (USD Million)

10.4.7.3.4. Value Creation Analysis

10.4.7.4. Padeliporfin (Steba biotech)

10.4.7.4.1. Target Patient Population

10.4.7.4.2. Sales Forecast (USD Million)

10.4.7.4.3. Net Present Value (USD Million)

10.4.7.4.4. Value Creation Analysis

10.4.7.5. Plinabulin (BeyondSpring Pharmaceuticals)

10.4.7.5.1. Target Patient Population

10.4.7.5.2. Sales Forecast (USD Million)

10.4.7.5.3. Net Present Value (USD Million)

10.4.7.5.4. Value Creation Analysis

10.4.7.6. VB-111 (VBL Therapeutics)

10.4.7.6.1. Target Patient Population

10.4.7.6.2. Sales Forecast (USD Million)

10.4.7.6.3. Net Present Value (USD Million)

10.4.7.6.4. Value Creation Analysis

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter), Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)

Product link: <https://marketpublishers.com/r/V6A64868934FEN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V6A64868934FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970